Johnson & Johnson has filed a Form 13F-HR with the Securities and Exchange Commission, disclosing its equity securities portfolio as of the close of business on September 30, 2026. The filing, submitted on October 26, 2026, identifies Marc Larkins as the secretary responsible for the report.
The information table lists a total of 14 equity securities held by the filer. The holdings are primarily concentrated in the biotechnology and healthcare sectors, with several positions representing significant share counts. Notable positions include MeiraGTx Holdings plc, which is held in the amount of 6,641,064 shares, and Fate Therapeutics Inc., held at 3,379,064 shares.
Other disclosed holdings include NanoBiTix S.A. sponsored ADSs with 5,623,816 shares, and Continuum Therapeutics Inc. Class A with 1,979,173 shares. The portfolio also includes positions in Cerebras Systems Inc., CVRX Inc., Neumora Therapeutics Inc., Protagonist Therapeutics Inc., Rapport Therapeutics Inc., Xencor Inc., and Standard BioTools Inc.
The filing indicates that the majority of the disclosed positions are classified as 'DFND,' which generally refers to 'Defensive' holdings. Additionally, Standard BioTools Inc. is listed with a different reporting code, though the share count for this specific holding is disclosed as 311,967.
